The Association of Palmitoylethanolamide with Luteolin Decreases Autophagy in Spinal Cord Injury

Rosalba Siracusa1 · Irene Paterniti1 · Giuseppe Bruschetta1 · Marika Cordaro1 · Daniela Impellizzeri1 · Rosalia Crupi1 · Salvatore Cuzzocrea1,2 · Emanuela Esposito1

Received: 9 March 2015 / Accepted: 26 June 2015 / Published online: 5 July 2015 © The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract Spinal cord injury (SCI) is a devastating condition of the central nervous system (CNS) often resulting in severe functional impairment and for which there are not yet restorative therapies. In the present study, we performed a widely used model of SCI to determine the neuroprotective propriety of palmitoylethanolamide (PEA) and the antioxidant effect of a flavonoid luteolin (Lut), given as a co-ultramicronized compound co-ultraPEALut. In particular, by western blot analysis and immunofluorescence staining, we investigated whether this compound (at the dose of 1 mg/kg) was able to modulate autophagy. Our results showed that treatment with co-ultraPEALut after SCI reduced the expression of proteins promoter of autophagy such as Beclin-1 and microtubule-associated protein 1A/1B-light chain 3 (MAP-LC3). In contrast, this compound decreased the levels of mammalian target of rapamycin (mTOR), p-Akt, and p-70S6K which are proteins that inhibit autophagy. These data confirmed that the protective role of co-ultraPEALut is associated with inhibition of excessive autophagy and regulation of protein degradation. Therefore, treatment with co-ultraPEALut could be considered as a possible therapeutic approach in an acute traumatic lesion like SCI.

Keywords Neuroprotection · Anti-inflammatory · Anti-oxidant · Autophagy · Spinal compression

Introduction Spinal cord injury (SCI) is defined as an acute traumatic lesion of neural elements in the spinal canal (spinal cord and cauda equina), resulting in a change, either temporary or permanent, in normal motor, sensory, or autonomic function. Spinal cord injury usually begins with a sudden, traumatic blow to the spine that causes local segmental damage to the spinal cord, which is called primary injury [1, 2]. The primary damage to the tissue is followed by a second phase of tissue degeneration, the secondary injury that can occur over weeks or even months. In secondary injury, acute inflammation can develop into a chronic process if feedback mechanisms fail to inhibit amplification of the inflammatory response. Chronic inflammation leads to a continuous influx of neutrophils, macrophages, lymphocytes, and eosinophils from the circulation, causing more destruction and scarring of tissue [3]. Cell death resulting from all of these mechanisms occurs through necrotic and apoptotic phenomena or autophagy.

Concern about autophagy has recently increased because of its potential role in neurodegenerative diseases, such as Parkinson’s and Alzheimer’s diseases, where autophagy may be a protective mechanism [4]. Earlier studies also demonstrated increased autophagic activity at lesion sites after cerebral hypoxia-ischemia (HI) injury [5], intracerebral hemorrhage (ICH) [6], and traumatic brain injury (TBI) [7, 8].

Autophagy, literally “self-eating, is now recognized as an intracellular catabolic mechanism for the degradation, elimination, and recycling of long-lived proteins and unwanted organelles in a cell during development and under stress conditions [9, 10]. Therefore, autophagy plays an important role...
in homeostasis and also to a kind of cell death, which is known as autophagic cell death [11, 12]. It begins with the formation of double-membraned vesicle that subsequently engulfs cytoplasmic components, including cytosolic proteins and organelles, to become autophagosomes (APs). APs fuse with lysosomes to form autolysosomes, and intra-autophagosomal components are degraded by lysosomal hydrolases. Several key molecular components participate in the initiation, progression, and completion of autophagy, like the mammalian target of rapamycin (mTOR) that inhibits autophagy, whereas Beclin 1 and LC3 promote it [8, 13]. However, autophagy seems to be a double-edged sword that protects cells when it is moderately activated, yet its excessive activation can induce autophagic cell death [14].

In recent years, the pathophysiology of SCI has been a focus of extensive studies; animal models have been proved to be important tools in this field and are employed to investigate the mechanisms of primary and secondary injury. Previous studies have shown that autophagy plays a key role in secondary injury in both animal models and human tissue by causing progressive degeneration of the spinal cord [15, 16]. However, the molecular pathway of secondary injury and the role of autophagy in the recovery of SCI remain unclear. Following acute spinal cord injury, an increase in mTOR expression and p70S6K activity also may be required for functional improvement [17]. The involvement of autophagic mechanism underlying spinal neuroprotective effects of palmitoylethanolamide (PEA) and luteolin (Lut) has never been investigated. Thus, we studied the autophagic pathway involved in spinal cord compression and to explore the effects of the treatment with a new co-ultramicronized composite of N-PEA and luteolin (Lut) on autophagy expression. This formulation (co-ultraPEALut) is based on association of anti-inflammatory PEA with anti-oxidant Lut on a 10:1 mass basis. We have previously demonstrated that treatment with co-ultraPEALut significantly reduces the inflammatory process in an ex vivo model of spinal cord organotypic cultures and in experimental mouse models of TBI [18, 7]. Furthermore, in this last model, we showed that co-ultraPEALut reduced autophagy after TBI [7].

Therefore, the aim of this study was to demonstrate that treatment co-ultraPEALut inhibited autophagy even after SCI, having neuroprotective effect.

**Methods**

**Animals**

CD1 mice (male 25–30 g; Harlan Nossan, Milan, Italy) were housed in a controlled environment and provided with standard rodent chow and water. Mice were housed in stainless steel cages in a room kept at 22±1 °C with a 12-h light, 12-h dark cycle. The animals were acclimatized to their environment for 1 week and had ad libitum access to tap water and rodent standard diet. The study was approved by the University of Messina Review Board for the care of animals. All animal experiments complied with regulations in Italy (D.M. 116/192) as well as the EU regulations (O.J. of E.C. L 358/1 12/18/1986).

**Co-ultramicronization Process of PEA and Lut**

The co-ultramicronization process was performed using jet mill equipment (Sturtevant, Inc., 348 Circuit Street Holler, MA, USA) with a chamber of 300 mm in diameter, operated with “spiral technology” and driven by compressed air at 10 to 12 bars. Crashing was determined by the high number of collisions that occurred among particles as a result of the high level of kinetic (not mechanical) energy. This process is effective not only in reducing product particle size but also in modifying crystalline structure. Scanning electron microscopy showed an intimate intermixing of PEA and Lut, while analysis by differential scanning calorimetry and X-ray diffraction indicated transformation into a crystalline form different from the original two, definable as “a higher energy content form.” The composite showed the following particle size distribution: 96 % <10 μm, 80 % <5 μm, and 40 % <2 μm. Co-ultraPEALut (Epitech Group s.r.l.) was dissolved in 10 % ethanol (Sigma-Aldrich, St Louis, MO, USA) and used at a concentration of 1 mg/kg in the in vivo study. The dose of co-ultraPEALut (1 mg/kg) used was based on previous in vivo studies [18].

**SCI**

Mice were anesthetized with intraperitoneal administration of ketamine and xylazine (2.6 and 0.16 mg/kg body weight, respectively). A longitudinal incision was made on the midline of the back, exposing the paravertebral muscles, as previously described [18]. These muscles were dissected away, the spinal cord was exposed via a four-level T5 to T8 laminectomy, and SCI was produced by extradural compression at T6 to T7 level, using an aneurysm clip with a closing force of 24 g. Following surgery, 1.0 cm³ of saline was administered subcutaneously in order to replace the blood volume lost during the surgery. During recovery from anesthesia, mice were placed on a warm heating pad and covered with a warm towel. The mice were individually housed in a temperature-controlled room at 27 °C. Food and water were provided to the mice ad libitum. During this time period, the animals’ bladders were manually voided twice a day until the mice were able to regain normal bladder function. In all injured groups, the spinal cord was compressed for 1 min. Sham animals were only subjected to laminectomy. Spinal cord tissues were taken at 24 h after trauma. Tissue segments contained the lesion...
(1 cm on each side of the lesion), according to counts of retrogradely labeled neurons at the origin of distinct descending motor pathways and to morphometric assessments of normal residual tissue at the injury epicenter, as previously described [19].

**Experimental Groups and Treatments**

**Mice Were Randomly Allocated into the Following Groups**

1. **Sham+vehicle**: mice were subjected to laminectomy, but the aneurysm clip was not applied and treated intraperitoneally (i.p.) with vehicle (n=30).
2. **Sham+co-ultraPEALut (10:1)** = same as the Sham+vehicle group, but co-ultraPEALut was administered at the final dose of 1 mg/kg i.p. at 1 and 6 h after laminectomy (n=30).
3. **SCI+vehicle**: mice were subjected to laminectomy and the aneurysm clip was applied (n=30).
4. **SCI+co-ultraPEALut (10:1)**: mice were subjected to SCI and administered co-ultraPEALut at the final dose of 1 mg/kg i.p. at 1 and 6 h after SCI (n=30).

**Western Blot Analysis**

Cytosolic and nuclear extracts were prepared with slight modifications of a published procedure [20]. Spinal cord tissues from each mouse were suspended in extraction Buffer A containing 0.2 mM PMSF, 0.15 mM peptatin, 20 mM leupeptin, 1 mM sodium orthovanadate, homogenized at the highest setting for 2 min, and centrifuged at 12,000 rpm for 4 min at 4 °C. Supernatants represented the cytosolic fraction. The pellets, containing enriched nuclei, were resuspended in Buffer B containing 1 % Triton X-100, 50 mM NaCl, 10 mM Tris–HCl pH 7.4, 1 mM EGTA, 1 mM EDTA, 0.2 mM PMSF, 20 mM leupeptin, and 0.2 mM sodium orthovanadate. After centrifugation 10 min at 12,000 rpm at 4 °C, the supernatants that we obtained were the nuclear proteins. Protein concentrations were estimated by the Bio-Rad protein assay using bovine serum albumin as standard. Briefly, samples were heated to 100 °C for 5 min, and equal amounts of protein were separated on 18 % SDS-PAGE gel and transferred to nitrocellulose membrane. Specific primary antibody, anti-anti-MAPLC3-α (1:5000; Santa Cruz Biotechnology), Beclin-1 (1:500; Santa Cruz Biotechnology), anti-p62 (1:1000; Cell Signaling), anti-mTOR (1:1000; Cell Signaling), anti-p70S6K (1:1000; Cell Signaling), and p-Akt (1:1000; Cell Signaling) were mixed in 1× PBS, 5 % w/v nonfat dried milk, 0.1 % Tween-20 (PMT), and incubated at 4 °C, overnight. After membranes were incubated with peroxidase-conjugated bovine anti-mouse IgG secondary antibody or peroxidase-conjugated goat anti-rabbit IgG (1:2000, Jackson ImmunoResearch) for 1 h at room temperature. To ascertain that blots were loaded with equal amounts of protein lysates, they were also incubated in the presence of the antibody against β-actin (1:5000; Santa Cruz Biotechnology). Signals were detected with enhanced chemiluminescence detection system reagent according to manufacturer’s instructions (SuperSignal West Pico Chemiluminescent Substrate, Pierce). The relative expression of the protein bands was quantified by densitometry with Bio-Rad Chemidoc™ XRS+ software and standardized to β-actin levels. Images of blots were scaled (8 bit/600-dpi resolution) were imported to analysis software (Image Quant TL, v2003). A preparation of commercially available molecular weight markers made of proteins of molecular weight 10 to 250 kDa was used to define molecular weight positions and as reference concentrations for each molecular weight.

**Immunofluorescence Staining**

After deparaffinization and rehydration, detection of GFAP, NeuN, Beclin-1, and MAPLC3-α was carried out after boiling in 0.1 M sodium citrate for 1 min. Nonspecific adsorption was minimized by incubating the section in 2 % (v/v) normal goat serum in PBS for 20 min. Sections were incubated with mouse monoclonal anti-NeuN (1:100, v/v Millipore), or with mouse monoclonal anti-GFAP (1:100, v/v Santa Cruz Biotechnology), or with polyclonal rabbit anti-Beclin-1 (1:100, v/v Santa Cruz, Biotechnology), or with rabbit anti-MAPLC3α (1:100, v/v Santa Cruz Biotechnology) antibody in a humidified chamber for O/N at 37 °C. Sections were washed with PBS and were incubated with secondary antibody FITC-conjugated anti-mouse Alexa Fluor-488 antibody (1:2000 v/v Molecular Probes, UK) and with TExAS RED-conjugated anti-rabbit Alexa Fluor-594 antibody (1:1000 in PBS, v/v Molecular Probes, UK) for 1 h at 37 °C. Sections were washed and for nuclear staining 4′,6-diamidino-2-phenylindole (DAPI; Hoechst, Frankfurt; Germany) 2 μg/ml in PBS was added. Sections were observed and photographed at ×20 magnification using a Leica DM2000 microscope (Leica). All images were digitalized at a resolution of 8 bits into an array of 2560×1920 pixels. Optical sections of fluorescence specimens were obtained using a HeNe laser (543 nm), a laser UV (361–365 nm), and an argon laser (458 nm) at a 1-min, 2-s scanning speed with up to 8 averages; 1.5 μm sections were obtained using a pinhole of 250. Contrast and brightness were established by examining the most brightly labeled pixels and applying settings that allowed clear visualization of structural details while keeping the highest pixel intensities close to 200. The same settings were used for all images obtained from the other samples that had been processed in parallel. Digital images were cropped and figure montages prepared using Adobe Photoshop CS5 (Adobe Systems; Palo Alto, CA).
Light Microscopy

For histopathological examination by standard hematoxylin and eosin (H&E) staining, the mice were anesthetized with ketamine and xylazine (2.6 and 0.16 mg/kg body weight respectively) 24 h after injury and then perfused transcardially with cold PBS (0.1 M). Tissues were removed under magnified vision, and segments containing the lesion (1 cm on each side of the lesion) were collected in 4 % paraformaldehyde for proper fixation and then dehydrated with graded ethanol and embedded in paraffin wax. Sections of 5-μm thickness were cut into longitudinal sections for the posterior area of the spinal cord, stained with H&E, and studied using light microscopy (Dialux 22 Leitz). Representative images were shown. Blinded histologic scoring (Fig. 1d) was performed on a 6-point scale: 0, normal; 1, 1–5 eosinophilic neurons within the gray matter area; 2, 5–10 eosinophilic neurons; 3, >10 eosinophilic neurons; 4, a small infarction (less than one-third of the gray matter area); 5, a moderate infarction (one-third to one-half of the gray matter area); and 6, a large infarction (more than half of the gray matter area).

Materials

Unless otherwise stated, all compounds were obtained from Sigma-Aldrich, while co-ultraPEALut was a kind gift from Epitech Group s.r.l. (Saccolongo, Italy). All other chemicals were of the highest commercial grade available. All stock solutions were prepared in non-pyrogenic saline (0.9 % NaCl, Baxter, Milan, Italy) or 10 % dimethyl sulfoxide.

Statistical Evaluation

All values in the figures and the text are expressed as mean±SEM. Results shown in the figures are representative of at least three experiments performed in different in vivo experimental days. In each experiment, we used five animals per group, unless otherwise indicated. The results were analyzed by one-way analysis of variance followed by a Bonferroni post hoc test for multiple comparisons. A p value of less than 0.05 was considered significant.

Fig. 1 Effects of co-ultraPEALut treatment on histological alterations of the spinal cord tissue 24 h after injury. Compared with the Sham-surgery mice (a, a1), significant histologic damage to the spinal cord was evident in mice subjected to SCI and treated with vehicle (b, b1). In the perilesional area of the SCI mice, edema was evident, as and alteration of the white matter. A significant reduction of SCI-associated damage was observed in the tissue samples collected from mice treated with co-ultraPEALut (c, c1). These data are also visible in the histological score (d). ***p<0.001 vs Sham; ###p<0.001 vs SCI
**Results**

**Effect of Co-ultraPEALut on Histological Parameters**

To evaluate the severity of the trauma at the level of the perilesional area at 24 h after injury, the sections obtained from each group were stained with hematoxylin and eosin (H&E). Compared with the sham group (Fig. 1a, b, see magnification higher a1 and b1, respectively), the SCI+vehicle group showed the presence of edema and alteration of the white matter (Fig. 1b, d, see magnification higher b1). Treatment with co-ultraPEALut attenuated acute inflammation and injury at 24 h after SCI (Fig. 1c, d, see magnification higher c1).

**Effect of Co-ultraPEALut on Autophagy After SCI: Expression of Beclin-1, p62, and MAP-LC3**

To investigate the mechanisms of autophagy after SCI, we examined levels of proteins involved in the regulation and formation of autophagosomes. Beclin-1 has a central role in autophagy because it interacts with various cofactors inducing autophagy. To compare the level of Beclin-1 protein between the injured and the treated spinal cord section, western blot analysis was performed. We showed that Beclin-1 expression dramatically increased in the spinal cord tissue (T6 to T8 tract) collected from mice subjected to SCI compared to the sham group, while the treatment with co-ultraPEALut significantly reduced SCI-induced Beclin-1 expression (Fig. 2a, see densitometry analysis in a1). For more accurate quantification of co-ultraPEALut effects on autophagy process, we examined levels of p62 by western blot analysis. We detected that p62 expression increased after SCI, whereas the treatment with co-ultraPEALut significantly reduced levels of this protein (Fig. 2b, see densitometry analysis in b1). p62 also interacts with a central component of the machine autophagy, autophagic marker MAP-LC3, and carries the altered proteins to degradation by autophagy. Therefore, western blot analysis, we showed that the ratio of LC3 I to LC3 II increased in untreated animals 24 h after injury, though this ratio significantly diminished to near sham levels of expression following co-ultraPEALut treatment (Fig. 2c, see densitometry analysis in c1), suggesting a reversal of autophagic activity upregulation seen following SCI.

![Fig. 2](image)

**Fig. 2** Effect of co-ultraPEALut about proteins promoting autophagy after SCI. Western blot analysis for Beclin-1, p62, and LC3 showed an increase of levels of these proteins in SCI group compared to the Sham group, whereas the treatment with co-ultraPEALut significantly reduced SCI-induced Beclin-1, p62, and LC3 expression (a, a1; b, b1; c, c1 respectively). The data are representative of at least three independent experiments. a **p<0.01 vs Sham; ###p<0.01 vs SCI. b **p<0.01 vs Sham; #p<0.05 vs SCI. c *p<0.05 vs Sham; #p<0.05 vs SCI.
Effect of Co-ultraPEALut on Beclin-1 and MAP-LC3 Expression by Immunofluorescence Staining

To better understand the Beclin-1 and MAP-LC3 expression in a specific population of cells, including neurons and astrocytes, the spinal cord sections (T6 to T8 tract) at 24 h after compression were double-stained for Beclin-1 (red) or MAP-LC3 (red) and various cell type markers, such as NeuN (green) for neurons and GFAP (green) for astrocytes (Figs. 3 and 4). In the double staining, the expression of Beclin-1 was observed in NeuN and GFAP-labeled cells of the injured SCI group (Fig. 3g–i and j–l, respectively) compared to Sham (Fig. 3a–c and d–f, respectively), whereas a treatment with co-ultraPEALut not only decreased significantly these proteins expression but also the double staining is less observed in both NeuN and GFAP (Fig. 3m–o and p–r, respectively). Similarly, at 24 h after SCI, double staining of LC3 revealed a strong co-localization with NeuN and GFAP in SCI group (Fig. 4g–i and j–l, respectively) compared to the Sham group (Fig. 4a–c and d–f, respectively), while treatment of co-ultraPEALut decreased significantly these protein expressions (Fig. 4m–o and p–r respectively).

Effect of Co-ultraPEALut on PI3K/Akt/mTOR Pathway After SCI

The PI3K/Akt/mTOR pathway is an intracellular signaling pathway important in regulating the cell cycle. mTOR is an upstream signal in the regulation of autophagy which is positively regulated by PI3K/Akt and results in the inhibition of autophagy. Therefore, by western blot analysis, we detected the activity of Akt/mTOR signaling pathways in our model in vivo. Our results showed that p-Akt and mTOR levels decreased significantly after SCI, compared with the Sham group, while co-ultraPEALut treatment increased p-Akt and mTOR expression, inhibiting autophagy (Fig. 5a, c, see densitometry analysis in a1 and b1, respectively). Moreover, a downstream target of mTOR signaling p70S6K activity was assessed by western blot analysis. p70S6K activity was suppressed in mice after SCI, whereas the co-ultraPEALut treatment enhanced activation of p70S6K signaling (Fig. 5c, see densitometry analysis in c1).

Discussion

The CNS is sensitive to mechanical injuries causing permanent functional deficits such as the case of patients who have SCI. The mechanical forces imparted to the spinal cord cause immediate tissue disruption, with direct axonal and neuronal injury, inducing the death of neurons. Moreover, neurons continue to die for hours or days after SCI, as a consequence of excitotoxicity, vascular dysfunction, and, in particular, because of the ensuing inflammatory response [21]. Inflammatory responses are a major component of secondary injury and...
play a central role in regulating the pathogenesis of acute and chronic SCI [22]. Functional recovery after SCI is often poor and, as yet, there are no nonsurgical therapies that have been successfully translated for use in the clinic. Therefore, there is a great need for drugs that will reduce post-traumatic, inflammation-related spinal cord damage because it has been reported that reducing inflammation decreases secondary degeneration and the functional deficit after SCI. In a previous study, we showed that co-ultraPEALut treatment (1 mg/kg) exerted beneficial effects in ex vivo model using spinal cord organotypic slice cultures and in vivo model of spinal cord compression injury in mice. Briefly, we found that co-ultraPEALut had anti-inflammatory, antioxidant, and neuroprotective properties [18].

Furthermore, recent studies demonstrated that another possible consequence of SCI is energy depletion, and this elicits autophagy [15, 16, 23]. Autophagy is a cellular catabolic degradation response to starvation or stress, whereby cellular proteins, organelles, and cytoplasm are engulfed, digested, and recycled to sustain cellular metabolism [9, 24]. Constitutive, basal autophagy also has an important homeostatic function, by maintaining protein and organelle quality control. Although most evidence supports a role for autophagy in sustaining cell survival, paradoxically, cell death resulting from progressive cellular consumption has been attributed to unrestrained autophagy [25–27]. The mechanisms that regulate the mutually opposed survival and death roles for autophagy are still unknown. The most plausible explanation is that catabolism through autophagy is predominantly survival-supporting, but that an imbalance in cell metabolism, where autophagic cellular consumption exceeds the cellular capacity for synthesis, promotes cell death [28].

Therefore, the aim of the present study was to explore new therapeutic approaches promoting survival of cells. In particular, we wanted to investigate whether the new compound co-ultraPEALut (at the dose of 1 mg/kg) was able to modulate autophagy promoting functional recovery after SCI.

In the first step, using H&E staining, we evaluated the effect of co-ultraPEALut on spinal cord at the level of the perilesional area at 24 h after injury. Histological analysis showed that mice, after SCI, presented edema and alteration of the white matter, while mice treated with co-ultraPEALut showed an attenuation of acute inflammation and injury after SCI.

In the second step, we studied the effects of this new compound on autophagy markers after SCI. In particular, we examined the levels of proteins that promote autophagy such as Beclin-1 and MAP-LC3. Beclin-1 is a protein that participates in the regulation of autophagy and has an important role in development, tumorigenesis, and neurodegeneration [29]. Beclin-1 functions as a scaffold for the formation of the PI3K complex, one of the first components recruited during the development of autophagosomes. During autophagy initiation and autophagosome formation, Beclin-1 binds microtubule-
associated protein 1A/1B-light chain 3 I (LC3I) that is converted to its membrane-bound form (LC3II), which then interacts with the ubiquitin-binding protein p62/sequestosome 1 [30–32]. Since p62 accumulates when autophagy is inhibited and decreased levels can be observed when autophagy is induced, p62 may be used as a marker to study autophagic flux [32]. In this study, we observed an increase of the expression of Beclin-1, LC3, and p62 after SCI that dramatically decreased after treatment with co-ultraPEALut. Furthermore, we wanted to assess whether Beclin-1 and MAP-LC3 were expressed in specific cells. Therefore, the spinal cord sections at 24 h after compression were double-stained for Beclin-1 or MAP-LC3 and various cell type markers, such as NeuN for neurons and GFAP for astrocytes. By immunofluorescence staining, we observed a strong co-localization of Beclin-1 and LC3 with NeuN and GFAP. These results showed that after SCI, the expression of these two proteins increases in neurons and astrocytes, while treatment with co-ultraPEALut reduces the levels of Beclin-1 and LC3 in both cell types.

Finally, we wanted to evaluate the effect of co-ultraPEALut on Akt/mTOR/p70S6K pathway that in autophagy has been considered a central regulatory pathway of the protein translation involved in regulating cell proliferation, growth, differentiation, and survival [33, 34]. mTOR kinase is a master regulator of autophagy directly suppressing autophagy. This protein is a central signal integrator that functions as a checkpoint with upstream Akt and downstream p70S6K being the two most important mediators [8]. Therefore, using western blot analysis, we detected mTOR expression and the phosphorylation of Akt after SCI. Our results indicated that p-Akt and mTOR levels decreased significantly after SCI, while co-ultraPEALut treatment increased expression of these proteins. Moreover, p70S6K activity was suppressed in mice after SCI, whereas the co-ultraPEALut treatment enhanced activation of p70S6K signaling. These data confirmed that the protective role of co-ultraPEALut is associated with inhibition of excessive autophagy via Akt/mTOR/p70S6K signals and regulation of protein degradation.

Fig. 5 Effect of co-ultraPEALut about proteins inhibiting autophagy after SCI. Western blot analysis for mTOR, p-Akt, and p70S6K showed a decrease of levels of these proteins in SCI group compared to the Sham group, whereas the treatment with co-ultraPEALut significantly increased SCI-induced mTOR, p-Akt, and p70S6K expression (a, a1; b, b1; c, c1 respectively). The data are representative of at least three independent experiments. a **p<0.01 vs Sham; #p<0.05 vs SCI. b ***p<0.01 vs Sham; ##p<0.01 vs SCI. c ***p<0.001 vs Sham; ###p<0.01 vs SCI.
We conclude that co-ultraPEALut treatment at the dose of 1 mg/kg is capable to improve neurobehavioral functions, and reduce apoptotic cell death and neuroinflammation, improving tissue structure after SCI [18]. In addition, our results suggest that SCI induces autophagic cell death at the lesion site; therefore, co-ultraPEALut treatment inhibiting autophagy in in vivo model of SCI has protective effect. In conclusion, co-ultraPEALut could be considered as a possible therapeutic target in an acute traumatic lesion like SCI.

Acknowledgments The authors would like to thank Maria Antonietta Medici for her excellent technical assistance during this study and Mr Francesco Soraci for his secretarial and administrative assistance and Miss Valentina Malvagni for her editorial assistance with the manuscript. This study was supported by PON 01_02512.

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflict of interest.

The study was approved by the University of Messina Review Board for the care of animals. All animal experiments complied with regulations in Italy (D.M. 116192) as well as the EU regulations (O.J. of E.C. L 358/1 12/18/1986).

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Zitman DR, Dustin ML et al (2005) ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 8(7):752–758
2. Amar AP, Levy ML (1999) Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury. Neurosurgery 44(5):1027–1034. discussion 1039-1040
3. Bareyre FM, Schwab ME (2003) Inflammation, degeneration and regeneration in the injured spinal cord: insights from DNA microarrays. Trends Neurosci 26(8):555–563
4. Nixon RA, Cruikshank AM, McNaught PM (2000) The endosomal-lysosomal system of neurons in Alzheimer’s disease pathogenesis: a review. Neurochem Res 25(9-10):1161–1172
5. Carlone MB, Blonder J, Baldini W (2008) Protective role of autophagy in neonatal hypoxia-ischemia induced brain injury. Neuropediatr 39(2):329–339. doi:10.1007/s81864-008-0222
6. He Y, Wan S, Liu S, Hua Y, Keep RF, Xi G (2008) Autophagy after injury in the brains of young mice. J Cereb Blood Flow Metab 28(5):897–905
7. Cordaro M, Impellizzeri D, Paterniti I, Bruschetta G, Siracusa R, De Stefano D, Cuzzocrea S, Esposito E (2014) Neuroprotective effects of co-ultraPEALut on secondary inflammatory process and autophagy involved in traumatic brain injury. J Neurotrauma. doi:10.1089/neu.2014.3460
8. Lai Y, Hickey RW, Chen Y, Bayir H, Sullivan ML, Chu CT, Kochanek PM, Dixon CE et al (2008) Autophagy is increased after traumatic brain injury in mice and is partially inhibited by the antioxidant gamma-glutamylcysteiny1 ethyl ester. J Cereb Blood Flow Metab 28(3):540–550
9. Levine B, Klionsky DJ (2004) Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6(4):463–477
10. Melendez A, Tallozcy Z, Seaman M, Eskelinen EL, Hall DH, Levine B (2003) Autophagy genes are essential for dauer development and life-span extension in C. elegans. Science 301(5638):1387–1391. doi:10.1126/science.1087782
11. Gozuacik D, Kimchi A (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23(16):2891–2906. doi:10.1038/sj.onc.1207521
12. Larsen KE, Sulzer D (2002) Autophagy in neurons: a review. Histochemistry and Histopathology 17(3):897–908
13. Park JM, Tougeron D, Huang S, Okamoto Y, Sina S, Vallyathan V, Schwartz DM, Aronovitz D, Jani P, Kim J, Metzler M, Luongo G, Cuzzocrea S (2014) Beclin 1 and UV/RAG confer protection from radiation-induced DNA damage and maintain centrosome stability in colorectal cancer cells. PLoS One 9(6):e100819. doi:10.1371/journal.pone.0100819
14. Ferraro E, Cecconi F (2003) Autophagic and apoptotic response to stress signals in mammalian cells. J Biochem Biophys 462(2): 210–219
15. Chen HC, Fong TH, Lee AL, Chu WT (2012) Autophagy is activated in injured neurons and inhibited by methylprednisolone after experimental spinal cord injury. Spine (Phila Pa 1976) 37(6):470–475. doi:10.1097/BRS.0b013e318221e859
16. Kami H, Ozawa T, Sekiguchi A, Yamaya S, Itoi E (2011) Induction of autophagy and autophagic cell death in damaged neural tissue after acute spinal cord injury in mice. Spine (Phila Pa 1976) 36(22):E1427–E1434. doi:10.1097/BRS.0b013e31820828c3a
17. Lu G, Detloff MR, Miller KN, Santi L, Houle JD (2012) Exercise modulates microRNAs that affect the PTEN/mTOR pathway in rats after spinal cord injury. Exp Neurol 231(1):447–456. doi:10.1016/j.expneurol.2011.01.018
18. Paterniti I, Impellizzeri D, Di Paola R, Navarra M, Cuzzocrea S, Esposito E (2013) A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury. J Neuroinflammation 10:91. doi:10.1186/1742-704x-10-91
19. Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Cuzzocrea S, Galuppo M, Esposito E (2011) Effects of palmitoylethanolamide on release of mast cell peptidases and neutrophilic factors after spinal cord injury. Brain Behav Immun 25(6):1099–1112. doi:10.1016/j.bbi.2011.02.006
20. Bethea JR, Castro M, Keane RW, Lee TT, Dietrich WD, Yezierski RP (1998) Traumatic spinal cord injury induces nuclear factor-kappaB activation. J Neurosci 18(9):3251–3259, discussion 1039–1040
21. Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Cuzzocrea S, Galuppo M, Esposito E (2011) Effects of palmitoylethanolamide on release of mast cell peptidases and neutrophilic factors after spinal cord injury. Brain Behav Immun 25(6):1099–1112. doi:10.1016/j.bbi.2011.02.006
22. Beethe JR, Castro M, Keane RW, Lee TT, Dietrich WD, Yezierski RP (1998) Traumatic spinal cord injury induces nuclear factor-kappaB activation. J Neurosci 18(9):3251–3260
23. Kwon BK, Tetzlaff W, Grauer JN, Beiner J, Vaccaro AR (2004) Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J 4(4):451–464. doi:10.1016/j.spinee.2003.07.007
24. Esposito E, Cuzzocrea S (2011) Anti-TNF therapy in the injured spinal cord. Trends Pharmacol Sci 32(2):107–115. doi:10.1016/j.tips.2010.10.009
25. Zhang HY, Wang ZG, Wu FZ, Kong XX, Yang J, Lin BB, Zhu SP, Lin L et al (2013) Regulation of autophagy and ubiquitinated protein accumulation by bFGF promotes functional recovery and neural protection in a rat model of spinal cord injury. Mol Neurobiol 48(3):452–464. doi:10.1007/s12035-013-8432-8
26. Mizushima N (2007) Autophagy: process and function. Genes Dev 21(22):2861–2873
27. Baehrecke EH (2005) Autophagy: dual roles in life and death? Nat Rev Mol Cell Biol 6(6):505–510
28. Debnath J, Baehrecke EH, Kroemer G (2005) Does autophagy contribute to cell death? Autophagy 1(2):66–74
27. Reef S, Zalckvar E, Shifman O, Bialik S, Sabanay H, Oren M, Kimchi A (2006) A short mitochondrial form of p19ARF induces autophagy and caspase-independent cell death. Mol Cell 22(4): 463–475. doi:10.1016/j.molcel.2006.04.014

28. Mathew R, Karantza-Wadsworth V, White E (2007) Role of autophagy in cancer. Nat Rev Cancer 7(12):961–967. doi:10.1038/nrc2254

29. Zhong Y, Wang QJ, Li X, Yan Y, Backer JM, Chait BT, Heintz N, Yue Z (2009) Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex. Nat Cell Biol 11(4):468–476. doi:10.1038/ncb1854

30. Park JM, Huang S, Wu TT, Foster NR, Sinicrope FA (2013) Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer Biol Ther 14(2): 100–107. doi:10.4161/cbt.22954

31. Tanida I, Ueno T, Kominami E (2008) LC3 and Autophagy. Methods Mol Biol 445:77–88. doi:10.1007/978-1-59745-157-4_4

32. Bjorkoy G, Lamark T, Pankiv S, Overvatn A, Brech A, Johansen T (2009) Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol 452:181-197. doi:10.1016/S0076-6879(08)03612-4

33. Pyronnet S, Sonenberg N (2001) Cell-cycle-dependent translational control. Curr Opin Genet Dev 11(1):13–18

34. Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103(2):253–262